Henrik J Ditzel
Overview
Explore the profile of Henrik J Ditzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
3485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kindt C, Ehmsen S, Traynor S, Policastro B, Nissen N, Jakobsen M, et al.
Front Oncol
. 2025 Feb;
14:1497093.
PMID: 39931212
Background: Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains...
2.
Jakobsen M, Traynor S, Nielsen A, Dahl C, Staehr M, Jakobsen S, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):21.
PMID: 39844304
Background: Despite promising preclinical studies, the application of DNA methyltransferase inhibitors in treating patients with solid cancers has thus far produced only modest outcomes. The presence of intratumoral heterogeneity in...
3.
Novak J, Nahacka Z, Oliveira G, Brisudova P, Dubisova M, Dvorakova S, et al.
Cell Rep
. 2025 Jan;
44(1):115154.
PMID: 39792553
Recent research has shown that mtDNA-deficient cancer cells (ρ cells) acquire mitochondria from tumor stromal cells to restore respiration, facilitating tumor formation. We investigated the role of Miro1, an adaptor...
4.
Ma S, Ong L, Jiang Z, Lee W, Lee P, Yusuf M, et al.
Cancer Cell
. 2024 Dec;
43(2):213-231.e9.
PMID: 39729997
Successful immunotherapy relies on both intratumoral and systemic immunity, which is yet to be achieved for most patients with cancer. Here, we identify P4HA1, encoding prolyl 4-hydroxylase 1, as a...
5.
Hansen K, Lyng M, Kodahl A, Asmussen J, Arshad A, Petersen H, et al.
BMC Med Genomics
. 2024 Nov;
17(1):274.
PMID: 39574115
Background: Genomic profiling of advanced solid cancer in patients with no further evidence based standard treatment options is a novel approach to identify potential experimental treatment options based on specific...
6.
Kindt C, Alves C, Ehmsen S, Kragh A, Reinert T, Vogsen M, et al.
Int J Cancer
. 2024 Aug;
155(12):2211-2222.
PMID: 39128978
Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improves outcome for patients with estrogen receptor-positive (ER+) metastatic breast cancer, but drug resistance and thus disease progression inevitably occur. Herein, we...
7.
Traynor S, Jakobsen M, Green T, Komic H, Palarasah Y, Pedersen C, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38886115
Cancer/testis antigens (CTAs) are widely expressed in melanoma and lung cancer, emerging as promising targets for vaccination strategies and T-cell-based therapies in these malignancies. Despite recognizing the essential impact of...
8.
Ormhoj M, Scarfo I, Cabral M, Bailey S, Lorrey S, Bouffard A, et al.
Clin Cancer Res
. 2024 May;
30(10):2286.
PMID: 38745479
No abstract available.
9.
Gammelgaard O, Terp M, Kirkin A, Johansen S, Traynor S, Vever H, et al.
Mol Cancer
. 2024 Jan;
23(1):6.
PMID: 38184565
Background: Adoptive cell transfer cancer immunotherapy holds promise for treating disseminated disease, yet generating sufficient numbers of lymphocytes with anti-cancer activity against diverse specificities remains a major challenge. We recently...
10.
Giger A, Ditzel H, Ditzel H, Ewertz M, Jorgensen T, Pfeiffer P, et al.
J Geriatr Oncol
. 2023 Nov;
15(1):101658.
PMID: 37939628
Introduction: Older patients with frailty starting oncological treatment are at higher risk of experiencing declining physical performance, loss of independence, and quality of life (QoL). This study examines whether comprehensive...